Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | PI4KA | P42356 | 2/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.59 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lodenosine SCHEMBL3482 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL16670086 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29663669 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29831913 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL8451244 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29421139 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29329162 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL30998176 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL22869478 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL97908 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741372-B2 | Guanylhydrazones useful for treating diseases associated with T cell activation | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20100080830-A1 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | PSIVIDA INC. (US) | 2010-04-01 | — | — | US | claimed |
| US-20060154892-A1 | Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis | LORI FRANCO | 2006-07-13 | — | — | US | claimed |
| US-20040115268-A1 | Systemic delivery of antiviral agents | CONTROL DELIVERY SYSTEMS, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004043435-A2 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-6194390-B1 | ADMINISTERING HYDROXYUREA AND A 2'-FLUOROPURINE-DIDEOXY-NUCLEOSIDE SELECTED FROM THE GROUP OF 2'-FLUORO-2',3'-DIDE-OXYADENOSINE,-DIDEOXYINOSINE, AND -DIDEOXYGUANOSINE WITH A CARRIER OR EXCIPIENT; VIRICIDES; RETROVIRUSES; PLANT VIRUSES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-02-27 | — | — | US | claimed |
| WO-1998038202-A1 | ANTIVIRAL PHOSPHONATE PRODRUGS OF NUCLEOSIDES AND NUCLEOSIDE ANALOGUES | DANA-FARBER CANCER INSTITUTE (US) | 1998-09-03 | — | — | WO | claimed |
| EP-0287313-B1 | Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus | US COMMERCE (US) | 1995-01-04 | — | — | EP | claimed |
| EP-0464137-A4 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | — | 1992-01-15 | — | — | EP | claimed |
| EP-0464137-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1992-01-08 | — | — | EP | claimed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | claimed |
| WO-1990011081-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1990-10-04 | — | — | WO | claimed |
| US-20250313905-A1 | METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-09 | — | — | US | disclosed |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-12364717-B2 | Compositions and methods for inhibiting seizures | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| EP-0464137-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1992-01-08 | — | — | EP | disclosed |
| WO-1991019726-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | WAKE FOREST UNIVERSITY (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | disclosed |
| WO-1990011081-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1990-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | EGFR 3271/4885ERBB2 3820/4885ADORA3 4797/4885 |
| US-20100080830-A1 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | HAVCR2, MAVS, PGF | EGFR 3385/4885ERBB2 3602/4885ADORA3 84/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | EGFR 2775/4885ERBB2 2690/4885ADORA3 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.